Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective Study.

Background: Conjunctivitis is among the most frequent adverse events (AEs) emerged in clinical trials for all biologic drugs approved for atopic dermatitis (AD). However, real-world comparative data on the incidence, risk factors, and management of conjunctivitis remain limited.

Objective: We aimed to compare the incidence, clinical features, and management of conjunctivitis in patients with moderate-to-severe AD treated with dupilumab or tralokinumab in a real-life setting.

JAK Inhibitors in Atopic Dermatitis: Does Weight Matter? A Real-World, Nationwide Retrospective Study: IL-AD (Italian Landscape Atopic Dermatitis).

Introduction: Janus kinase (JAK) inhibitors are effective systemic treatments for moderate-to-severe atopic dermatitis (AD), rapidly controlling symptoms and improving quality of life. However, the impact of body mass index (BMI) on therapeutic response remains unclear.

Methods: This multicenter retrospective study analyzed data from 388 adult AD patients treated with upadacitinib, abrocitinib, or baricitinib across 25 Italian dermatology centers between May 2022 and July 2024.

Therapeutic Outcomes Across JAK Inhibitors in Prurigo Nodularis.

Background: Prurigo nodularis (PN) is a debilitating skin condition. When inadequate disease control is achieved or other systemic therapies are contraindicated, JAK inhibitors may be considered although real-world evidence remains limited.

Objective: To investigate clinical findings and treatment outcomes among patients diagnosed with PN and undergoing JAK inhibitors in real-world setting.

Management Strategies for Generalised Granuloma Annulare: A Systematic Review of Current and Emerging Therapies.

Generalised Granuloma Annulare (GGA) is a chronic inflammatory skin disorder with no standard treatment. Since the last review in 2013, new treatments and varied responses have highlighted the need for an updated synthesis to guide clinical decisions. This systematic review aimed to evaluate the epidemiology, comorbidities and treatment outcomes in patients with GGA, synthesising evidence from published studies to provide insights into both conventional and emerging therapeutic strategies.

Clinical Course of Atopic Dermatitis after Dupilumab Discontinuation: A Multicenter Real-World Study.

Introduction: Limited data exist on the clinical course of atopic dermatitis (AD) after the discontinuation of dupilumab. This study aims to assess disease progression following dupilumab discontinuation.

Methods: A multicenter, retrospective study was conducted on 208 patients with severe AD who discontinued dupilumab for reasons unrelated to inefficacy.

Effectiveness and Safety of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis and Previous Failures of Th2 Biologics: A Propensity Score-Matched Study.

Introduction: Real-world data comparing patients with atopic dermatitis (AD) initially treated with upadacitinib versus those previously treated with biologics or other JAK inhibitors are limited.

Methods: We conducted a retrospective multicenter study of 524 patients with moderate-to-severe AD treated with upadacitinib to assess clinical outcomes over 52 weeks. A sub-analysis of 316 patients compared outcomes between those who had previously failed Th2 biologics (group A) and those who discontinued these treatments for reasons other than inefficacy or were bio-naïve (group B), using a Propensity Score matching method.

Emerging Therapies in the Treatment of Prurigo Nodularis: Biological Therapy and Systematic Review of Literature.

Introduction: Prurigo nodularis (PN) is a chronic, intensely pruritic dermatosis characterized by hyperkeratotic nodules and a persistent itch-scratch cycle. Recent insights highlight the role of T helper type 2 cell (Th2)-driven immune dysregulation and neuroinflammation, with cytokines such as interleukin (IL)-4, IL-13, and IL-31 implicated in disease pathogenesis. PN is associated with significant morbidity and multiple comorbidities, and conventional therapies often yield suboptimal outcomes, underscoring the need for targeted treatments.

Beyond the surface: an uncommon case of subcutaneous mycosis induced by an insect bite.

Deep cutaneous and subcutaneous infections caused by dermatophytes are exceptionally uncommon, typically occurring through traumatic inoculation. This clinical report details the complex dermatological journey of a young, immunocompetent 24-year-old girl who reported a rare case of a subcutaneous mycosis caused by Microsporum gypseum. The patient presented with an annular erythematous plaque with centered papules on her left hand, which she referred to as stemming from an insect bite.

Effectiveness of Tralokinumab Across Atopic Dermatitis Phenotypes.

: Tralokinumab, a fully human monoclonal antibody targeting IL-13, has shown efficacy and safety in clinical trials and real-life studies for atopic dermatitis (AD). However, data on its effectiveness across AD phenotypes are limited. : A multicentric study evaluated tralokinumab's efficacy over 52 weeks in 416 severe AD patients.

Tumoral Melanosis: A Case Series of a Rare Clinical Entity.

Tumoral melanosis (TM) is a rare entity thought to result from the complete regression of melanoma. Clinically, TM resembles malignant melanocytic lesions, presenting as hyperpigmented flat or papulonodular lesions. Histologically, TM lacks melanocytes, instead showing inflammation, fibrosis, and melanophages.

Safety and Effectiveness of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis Who Smoke: a 2-Year Real-Life Multicenter Study.

Background: Atopic dermatitis (AD) is a chronic inflammatory skin condition that significantly impairs the quality of life. Recent advancements in systemic therapies, such as Janus kinase (JAK) inhibitors, offer very effective new treatment options. However, concerns regarding potential adverse events, including cardiovascular and thromboembolic risk, have emerged from clinical studies and call for further real-life investigations.

Efficacy and drug survival of tralokinumab in patients with severe atopic dermatitis: an 18-month multicentre study.

Background: Tralokinumab has demonstrated efficacy in the treatment of atopic dermatitis (AD) in clinical trials and real-world settings. However, there are limited data regarding the long-term use of tralokinumab in real-world settings. Here, we report the findings of a multicentre Italian study conducted to address this knowledge gap.

One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis.

Introduction: Currently, limited data are available on long-term use of dupilumab to treat atopic dermatitis (AD) in a multinational real-world setting. The aim of this analysis was to report the interim 1-year data for patients with AD enrolled in the GLOBOSTAD registry, including treatment patterns, dupilumab effectiveness and safety, and healthcare burden.

Methods: GLOBOSTAD is an ongoing, 5-year, multinational, prospective, observational study of adult/adolescent (aged ≥ 12 years at baseline) patients with AD who initiated dupilumab in real-world settings according to their local country-specific prescribing guidelines.

Drug Survival, Retention, and Persistence of Dupilumab in Adults and Adolescents with Atopic Dermatitis: A Narrative Literature Review.

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin condition that can have a negative impact on a patient's quality of life. Long-term effectiveness is required to manage the symptoms of AD (skin inflammation, eczematous lesions, and itching). Because some of the systemic immunosuppressants used to treat AD have been associated with serious adverse events (AEs), other safer, more effective options, including dupilumab, have been proven effective long-term for treatment of adult and adolescent patients with moderate-to-severe AD.

Evaluation of the incidence of melanoma and non-melanoma skin cancer in patients with systemic lupus erythematosus and systemic sclerosis.

Background: The incidence of skin cancer in patients with systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) has only been investigated with retrospective studies enrolling a low number of patients. The aims of our study were to assess the incidence of skin cancer in two large cohorts of patients, one with SLE and the other with SSc and investigating possible risk factors.

Methods: Ninety SLE, 53 SSc patients and 392 control subjects were enrolled.

Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: a real-world multicentre Italian study of 2576 patients.

Background: The efficacy and safety of dupilumab in atopic dermatitis (AD) have been defined in clinical trials but limited real-world evidence on long-term treatment outcomes is currently available to inform clinical decisions.

Objectives: To describe the long-term effectiveness and safety of dupilumab up to 48 months in patients with moderate-to-severe AD.

Methods: A multicentre, retrospective, dynamic cohort study was conducted to assess long-term effectiveness and safety of dupilumab in patients with moderate-to-severe AD in a real-world setting.

A Multidisciplinary Approach Is Beneficial in Atopic Dermatitis.

Atopic dermatitis (AD) is a highly heterogeneous chronic inflammatory skin disorder that is frequently associated with a plethora of comorbidities. AD is, therefore, considered a systemic disease impacted by a considerable burden and leading to poor quality of life, especially in patients with moderate-to-severe disease. Since atopic and non-atopic comorbidities can further worsen the disease course, accurate establishment of the patient's individual intrinsic risk profile and needs is crucial and may help in guiding the selection of the best treatment option.